Global Leukemia Therapeutics Market to Reach US$ 12 Billion By 2022

Florida, January 22, 2018: Uncontrolled growth of cells is caused due to mutation to genes in cancer. The uncontrolled grown cell again moves from one part of body to another through blood and lymph system. There are different types of cancer out of which Leukemia is one. Cancer which is formed in blood tissues is called as Leukemia. Leukemia occurs due to the uncontrolled growth of with blood cells in the bone marrow. White blood cells are the protectors of our body from different infections. Leukemia is the most common type of cancer that is caused among adult males because they are not diagnosed at proper time. The most familiar syndrome of Leukemia is weight loss, night sweats, fever, frequent infections and enlarged liver size. There are different types of Leukemia out of which are acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia.

The Global Leukemia Therapeutic Market is expected to exceed more than US$ 11.97 Billion by 2022 at a CAGR of 4% in the given forecast period.

You Can Browse Full Report: https://www.marketresearchengine.com/leukemia-therapeutics-market

The Global Leukemia Therapeutic Market is segmented on the lines of its therapy, type and regional. Based on therapy segmentation it covers Chemotherapy, Biological Therapy, Radiation therapy, Targeted therapy, other. Based on type segmentation it covers Chronic leukemia, acute leukemia, others.

The Global Leukemia Therapeutic Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

The major driving factors of Global Leukemia Therapeutic Market are as follows:
• Novel developments for drug discovery approaches
• Increase incidence number of target disease
• Increase aging population
• Not much competition in the market

The restraining factors of Global Leukemia Therapeutic Market are as follows:
• Expensive treatment
• Adverse effect of the treatment

This report provides:

1) An overview of the global market for Global Leukemia Therapeutic Market and related technologies.
2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2022.
3) Identifications of new market opportunities and targeted promotional plans for Global Leukemia Therapeutic Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.

REPORT SCOPE:

The scope of the report includes a detailed study of global and regional markets on Global Leukemia Therapeutic Market with the reasons given for variations in the growth of the industry in certain regions.


The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include F. Hoffmann-La Roche Ltd., Amgen, Bristol-Myers Squibb, Novartis International AG., Pfizer, Teva Pharmaceuticals, GlaxoSmithKline plc. Genzyme Corporation, AbbVie Inc. and ARIAD Pharmaceuticals, Inc. among others. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

Request Sample Report: https://www.marketresearchengine.com/leukemia-therapeutics-market

Table of Contents
1 INTRODUCTION
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 DEFINING LEUKEMIA
3.1.1 DIAGNOSIS
3.1.1.1 Biopsy and bone marrow aspiration
3.1.1.2 Complete blood count (CBC) and differential
3.1.1.3 Philadelphia chromosome’s presence
3.1.1.4 Spinal tap (lumbar puncture) and cerebrospinal fluid (CSF) analysis
3.1.1.5 Immunophenotyping or phenotyping by flow cytometry
3.1.1.6 Polymerase chain reaction (PCR)
3.1.2 LEUKEMIA PREVALENCE
3.1.3 INCIDENCE & MORTALITY
3.2 TYPES OF LEUKEMIA
3.2.1 BASED ON DEVELOPMENTAL & PROGRESSION RATE
3.2.1.1 Chronic leukemia
3.2.1.2 Acute leukemia
3.2.2 BASED ON BONE MARROW CELLS AFFECTED
3.2.2.1 Lymphocytic (lymphoblastic) leukemia
3.2.2.2 Myelogenous (also called myeloid) leukemia
3.2.3 BASED ON DEVELOPMENT/PROGRESSION RATE & TYPE OF BONE MARROW CELLS AFFECTED
3.2.3.1 Acute Lymphocytic Leukemia (ALL)
3.2.3.2 Chronic Lymphocytic Leukemia (CLL)
3.2.3.2.1 B-cell CLL
3.2.3.2.2 T-cell CLL
3.2.3.2.3 Hairy cell leukemia
3.2.3.2.4 Large granular lymphocytic leukemia
3.2.3.3 Acute Myeloid Leukemia (AML)
3.2.3.4 Chronic Myeloid Leukemia (CML)
3.3 STAGES/PHASES OF LEUKEMIA
3.3.1 ACUTE LYMPHOCYTIC LEUKEMIA
3.3.1.1 Childhood ALL
3.3.1.1.1 Standard (low) risk
3.3.1.1.2 High risk
3.3.1.1.3 Recurrent
3.3.1.2 Adult ALL
3.3.1.2.1 Untreated adult ALL
3.3.1.2.2 Adult ALL in remission
3.3.1.2.3 Recurrent adult ALL
3.3.2 CHRONIC LYMPHOCYTIC LEUKEMIA
3.3.2.1 Stage 0
3.3.2.2 Stage I
3.3.2.3 Stage II
3.3.2.4 Stage III
3.3.2.5 Stage IV
3.3.3 ACUTE MYELOID LEUKEMIA
3.3.3.1 Childhood AML
3.3.3.2 Adult AML
3.3.4 CHRONIC MYELOGENOUS LEUKEMIA
3.3.4.1 Chronic stage
3.3.4.2 Accelerated stage
3.3.4.3 Blastic stage
3.3.4.4 Relapse
3.4 MARKET STRUCTURE
3.4.1.1 Key therapies
3.4.1.1.1 Chemotherapy
3.4.1.1.2 Stem cell/bone marrow transplant
3.4.1.1.3 Radiation therapy
4 LEUKEMIA MARKET DYNAMICS
5 LEUKEMIA PRODUCT MARKET
6 LEUKEMIA DRUG PIPELINE (PHASE III)
7 GEOGRAPHIC ANALYSIS
8 COMPETITIVE LANDSCAPE
9 COMPANY PROFILES
9.1 AMBIT BIOSCIENCES CORPORATION
9.2 ARIAD PHARMACEUTICALS INC
9.3 BIOGEN IDEC INC.
9.4 BRISTOL-MYERS SQUIBB
9.5 CELGENE CORPORATION
9.6 CEPHALON INC
9.7 CLAVIS PHARMA ASA
9.8 EISAI CO. LTD.
9.9 ERYTECH PHARMA
9.10 GENMAB A/S
9.11 GENZYME CORPORATION
9.12 GLAXOSMITHKLINE PLC
9.13 NOVARTIS INTERNATIONAL AG
9.14 PFIZER INC
9.15 ROCHE HOLDING AG
9.16 SUNESIS PHARMACEUTICALS INC
9.17 TALON THERAPEUTICS INC

About MarketResearchEngine.com
Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact
Company Name: Market Research Engine
Contact Person: John Bay
Email: john@marketresearchengine.com
Phone: +1-855-984-1862
Country: United States
Website: https://www.marketresearchengine.com/

Address: 3422 SW 15 Street, Suite #8942, Deerfield Beach, FL 33442, United States

This release was published on openPR.